Background
A member being treated for type 2 diabetes had activeprescriptions for both a GLP-1 receptor agonist and a DPP-4 inhibitor. Bothmedication classes act through the incretin pathway. Current diabetes treatmentguidance does not recommend using them together because adding a DPP-4inhibitor to GLP-1 therapy doesn’t provide meaningful additional glucoselowering. The overlap can add unnecessary medication cost, treatment burden andpotential side effects without a clear clinical benefit.
What we did
HyperCare flagged the duplicate therapy duringpoint-of-sale review and PharmPix’s clinical team contacted the prescriber toconfirm the intended treatment plan. The team shared clinical guidancesupporting discontinuation of the DPP-4 inhibitor when a GLP-1 receptor agonistis being used, while recognizing that the final treatment decision remains withthe prescriber and patient.
The impact
- Identified therapy overlap before dispensing
- Supported guideline-aligned diabetes treatment
- Helped avoid unnecessary medication cost and treatment burden
- Reinforced clinically appropriate prescribing at the point of sale
Clinical protection happens at the pointdecisions are made. PharmPix helps identify potential medicationrisks and brings clinical protection to the moments that matter.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.